Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Onivyde

- PMLiVE

Ipsen promotes Alexis Vandier as general manager, France

He will also join the French biopharma group’s global speciality leadership team

- PMLiVE

Ipsen’s liver cancer treatment clears phase III trial

Cabometyx on track for new liver cancer indication

- PMLiVE

Ian Weatherhead joins Ipsen

Takes up corporate communications role at the French pharma firm

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

NICE gives green light to Ipsen’s Cabometyx

Backs the medicine’s use for patients with advanced kidney cancer

- PMLiVE

Ipsen appoints executive vice president

Alexandre Lebeaut also set to be chief scientific officer

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

- PMLiVE

Ipsen appoints new executive vp and president, primary care

Benoit Hennion will also join the executive leadership team

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

- PMLiVE

Cellectis gets FDA nod for ‘off-the-shelf’ CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

- PMLiVE

Ipsen boosts specialty care and R&D leadership teams

Harout Semerjian and Dr Sotirios Stergiopoulos join

- PMLiVE

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links